BiotechTube

Moisturizer A, F#9155-005

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skin

Conditions

Skin, Skin Care, Skin Cream

Trial Timeline

Oct 23, 2015 → Apr 7, 2016

NCT ID
NCT04510103

About Moisturizer A, F#9155-005

Moisturizer A, F#9155-005 is a pre-clinical stage product being developed by Johnson & Johnson for Skin. The current trial status is completed. This product is registered under clinical trial identifier NCT04510103. Target conditions include Skin, Skin Care, Skin Cream.

What happened to similar drugs?

16 of 20 similar drugs in Skin were approved

Approved (16) Terminated (4) Active (4)
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + Standard of Care (SOC)MerckApproved
✅Daptomycin + VancomycinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅DaptomycinNovartisApproved
✅Tigecycline + ampicillin-sulbactamPfizerApproved
✅linezolid + vancomycinPfizerApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04510103Pre-clinicalCompleted

Competing Products

20 competing products in Skin

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
29
LY3041658 + PlaceboEli LillyPhase 1
29
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
29
levofloxacinJohnson & JohnsonPhase 2/3
38
levofloxacinJohnson & JohnsonPhase 3
40
CeftobiproleJohnson & JohnsonPhase 1
29
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
36
LevofloxacinJohnson & JohnsonPhase 3
40
CeftobiproleJohnson & JohnsonPhase 1
29
Levodopa-carbidopa intestinal gelAbbViePhase 3
40
IressaAstraZenecaPhase 2
35
Daptomycin + VancomycinAstraZenecaPhase 3
40
SarizotanMerckPre-clinical
18
Pembrolizumab + EDP1503MerckPhase 2
27
testosterone gel + Comparator: placeboMerckPhase 1
29
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
45
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
35
Pembrolizumab + VismodegibMerckPhase 1/2
32